-
- Karthik Nagaraj, Nicolas Vandenbussche, and Peter J Goadsby.
- Department of Neurology, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.
- Neurol India. 2021 Mar 1; 69 (Supplement): S59-S66.
BackgroundMedications targeting the calcitonin gene-related peptide (CGRP) pathway are exciting and novel therapeutic options in the treatment of migraine.ObjectiveIn this article, we have reviewed the role of these CGRP monoclonal antibodies in patients with episodic migraine.Materials And MethodsWe did an extensive literature search for all phase 2 and 3 studies involving CGRP monoclonal antibodies in episodic migraine.ResultsErenumab, fremanezumab, galcanezumab, and eptinezumab have all undergone phase 3 trials and have been found to be effective for episodic and chronic migraine. They have the advantage of being targeted therapies for migraine with very favorable adverse effect profiles comparable to placebo. Importantly, they are effective in subgroups of patients who have failed previous preventive therapies.ConclusionIncreasing use of these medications will certainly revolutionize the treatment and outlook for patients with migraine all over the world.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..